Invest24

Appearance

Altria(奥驰亚) MO ​

PMTA (Premarket Tobacco Product Application) reviews

Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products.

In combustibles, we own

  • Philip Morris USA Inc. (PM USA), the most profitable U.S. cigarette manufacturer, and
  • John Middleton Co. (Middleton), a leading U.S. cigar manufacturer.

Our smoke-free portfolio includes ownership of

  • U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer,
  • Helix Innovations LLC (Helix), a leading manufacturer of oral nicotine pouches, and
  • NJOY, LLC (NJOY), an e-vapor manufacturer with products covered by marketing granted orders from the U.S. Food and Drug Administration (FDA).

Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products.

Our equity investments include Anheuser-Busch InBev SA/NV (ABI), the world’s largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.

The brand portfolios of our operating companies includeMarlboro®, Black & Mild®, Copenhagen®, Skoal®, on!® and NJOY®).

Dividend Information ​

  • 2009年，拆分PMI之后第一年: 1.32
  • 2025年，4.16%

年符合增长率7%。

Investors ​

News ​

RICHMOND, Va.--(BUSINESS WIRE)-- Altria Group, Inc. (NYSE:MO) announces that we have entered into a definitive agreement to acquire NJOY Holdings, Inc. (NJOY) for approximately $2.75 billion in cash payable at closing (Transaction). The Transaction terms include additional $500 million in cash payments that are contingent upon regulatory outcomes with respect to certain NJOY products.

British American Tobacco(英美烟草) made a bid for Reynolds American(雷诺美国), maker of Camels, in 2016.

Last year(2018) Altria spent $12.8bn on 35% of Juul Labs, a maker of popular high-nicotine vaporisers. It paid $1.8bn for 45% of Cronos Group, a cannabis company from Canada (which, along with some American states, has legalised pot).

PMI has spent $6bn since 2008 to develop IQOS, a smoke-free device which heats tobacco and is expected to represent 40% of its sales by 2025, up from 14% last year. In April it won approval from the Food and Drug Administration (FDA) to sell IQOS in America, starting next month (under an existing licensing agreement with Altria).

Worldwide cigarette sales fell by 4.5% in 2018, to $714bn, and may continue to decline. The FDA’s proposed rules on nicotine content, to make smokes “minimally addictive”, could cut profits of American tobacco firms by half, say analysts at Morgan Stanley, a bank.

By contrast, e-cigarette revenues may grow by more than 8% annually over the next five years, from $11bn today, according to Mordor Intelligence, a research firm.

As a result of the spin-off, each Altria stockholder will receive one share of PMI common stock for each share of Altria common stock held as of 5:00 p.m. New York City Time on March 19, 2008, the record date. The distribution of PMI shares will take place on March 28, 2008.

Following the spin-off, Altria common stock will continue to trade on the New York Stock Exchange under the ticker symbol “MO” and PMI common stock will trade on the New York Stock Exchange under the ticker symbol “PM.”

2028 Enterprise Goals ​

  • Deliver a mid-single digits adjusted diluted EPS* compounded annual growth rate in 2028 from a $4.87 base in 2022.
  • A progressive dividend goal targeting mid-single digits dividend per share growth annually through 2028.
  • Target a debt-to-Consolidated EBITDA ratio of approximately 2.0x.

Earnings ​

2025Q3 ​

In August, we announced our 60th dividend increase in 56 years, and yesterday, our Board authorized an expansion of our share repurchase program.

We are raising the lower-end of our 2025 full-year guidance and now expect to deliver adjusted diluted EPS in a range of $5.37 to $5.45. This range represents a growth rate of 3.5% to 5.0% from a base of $5.19 in 2024.

In the third quarter, we repurchased 1.9 million shares at an average price of $60.13, for a total cost of $112 million.

Through the first nine months, we repurchased 12.3 million shares at an average price of $58.08, for a total cost of $712 million.

Yesterday, our Board of Directors (Board) authorized the expansion of our existing share repurchase program from $1 billion to $2 billion, which now expires on December 31, 2026.

In August, our Board increased our regular quarterly dividend by 3.9%, marking the 60th increase in the past 56 years. Our current annualized dividend rate is $4.24 per share.

We maintain our progressive dividend goal that targets mid-single digits dividend per share growth annually through 2028.

2025Q2 ​

“We are raising the lower-end of our 2025 full-year guidance and now expect to deliver adjusted diluted EPS in a range of $5.35 to $5.45. This range represents a growth rate of 3.0% to 5.0% from a base of $5.19 in 2024.”

In the second quarter, we repurchased 4.7 million shares at an average price of $58.63, for a total cost of $274million.
Through the first half, we repurchased 10.4 million shares at an average price of $57.71, for a total cost of $600 million

We paid dividends of $1.7 billion and $3.5 billion in the second quarter and first half, respectively.

2025Q1 ​

On March 31, 2025, the ITC’s importation ban and cease-and-desist orders applicable to NJOY ACE (ACE) went into effect. While NJOY discontinued shipments of ACE to wholesalers as of March 24, 2025, retailers are permitted to sell through their existing inventory of ACE.

As a result of the ITC orders going into effect, we recorded a non-cash impairment charge of $873 million to the e-vapor reporting unit goodwill in the first quarter of 2025. There was no income tax benefit associated with the impairment because it is non-deductible for tax purposes.

JUUL’s patent litigation against NJOY has resulted in the U.S. International Trade Commission’s (ITC) issuing an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE (NJOY’s pod-based e-vapor product) in the U.S.

2024Q4 ​